Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
Jiann Wei Yeoh, Erin J. Campbell, Morgan H. James, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Sleep, insomnia, and depression
Dieter Riemann, Lukas B. Krone, Katharina Wulff, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 1, pp. 74-89
Open Access | Times Cited: 580
Motivational activation: a unifying hypothesis of orexin/hypocretin function
Stephen V. Mahler, David E. Moorman, Rachel J. Smith, et al.
Nature Neuroscience (2014) Vol. 17, Iss. 10, pp. 1298-1303
Open Access | Times Cited: 358
A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?
Morgan H. James, Stephen V. Mahler, David E. Moorman, et al.
Current topics in behavioral neurosciences (2016), pp. 247-281
Closed Access | Times Cited: 169
Etiological theories of addiction: A comprehensive update on neurobiological, genetic and behavioural vulnerability
Mounir Ouzir, M. Errami
Pharmacology Biochemistry and Behavior (2016) Vol. 148, pp. 59-68
Closed Access | Times Cited: 103
Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders
Morgan H. James, Erin J. Campbell, Christopher V. Dayas
Current topics in behavioral neurosciences (2017), pp. 197-219
Open Access | Times Cited: 102
The key role of insomnia and sleep loss in the dysregulation of multiple systems involved in mood disorders: A proposed model
Laura Palagini, Célyne Bastien, Donatella Marazziti, et al.
Journal of Sleep Research (2019) Vol. 28, Iss. 6
Open Access | Times Cited: 99
A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects
Pascal Bonaventure, Sujin Yun, Philip L. Johnson, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 352, Iss. 3, pp. 590-601
Open Access | Times Cited: 94
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment
Laura Palagini, Pierre A. Geoffroy, Matteo Balestrieri, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 4
Closed Access | Times Cited: 25
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Taro Kishi, Shinji Matsunaga, Nakao Iwata
PLoS ONE (2015) Vol. 10, Iss. 8, pp. e0136910-e0136910
Open Access | Times Cited: 72
Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner
David E. Moorman, Morgan H. James, Elisabeth A. Kilroy, et al.
European Journal of Neuroscience (2016) Vol. 43, Iss. 5, pp. 710-720
Open Access | Times Cited: 67
Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin‐1 receptor antagonist in rats
Morgan H. James, Hannah E. Bowrey, Colin M. Stopper, et al.
European Journal of Neuroscience (2018) Vol. 50, Iss. 3, pp. 2602-2612
Open Access | Times Cited: 64
Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy
Cliff H. Summers, Jazmine D. W. Yaeger, Clarissa D. Staton, et al.
Brain Research (2018) Vol. 1731, pp. 146085-146085
Open Access | Times Cited: 59
Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors
F. Woodward Hopf
Neuropharmacology (2020) Vol. 168, pp. 108013-108013
Open Access | Times Cited: 50
Exercise reverses the effects of early life stress on orexin cell reactivity in male but not female rats
Morgan H. James, Erin J. Campbell, Frederick R. Walker, et al.
Frontiers in Behavioral Neuroscience (2014) Vol. 8
Open Access | Times Cited: 65
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Acid–base dysregulation and chemosensory mechanisms in panic disorder: a translational update
Lauren L. Vollmer, Jeffrey R. Strawn, Renu Sah
Translational Psychiatry (2015) Vol. 5, Iss. 5, pp. e572-e572
Open Access | Times Cited: 57
The contribution of orexins to sex differences in the stress response
Laura A. Grafe, Seema Bhatnagar
Brain Research (2018) Vol. 1731, pp. 145893-145893
Open Access | Times Cited: 54
Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms
Yi‐Ling Chien, Chih‐Min Liu, Jia‐Chi Shan, et al.
Psychoneuroendocrinology (2014) Vol. 53, pp. 1-9
Closed Access | Times Cited: 53
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Erin J. Campbell, Nathan J. Marchant, Andrew J. Lawrence
Brain Research (2018) Vol. 1731, pp. 145902-145902
Closed Access | Times Cited: 50
Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Adam Savitz, Ewa Wajs, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2021) Vol. 24, Iss. 12, pp. 965-976
Open Access | Times Cited: 40
Microglia in Alzheimer’s Disease: An Unprecedented Opportunity as Prospective Drug Target
Bhargavi Kulkarni, Natália Martins, Dileep Kumar
Molecular Neurobiology (2022) Vol. 59, Iss. 5, pp. 2678-2693
Closed Access | Times Cited: 25
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
Seltorexant for major depressive disorder
K.L. Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
The EEG as an index of neuromodulator balance in memory and mental illness
Costa Vakalopoulos
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top